LY-4101174 is under clinical development by Eli Lilly and Co and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition ...
Lilly is headquartered in Indianapolis, Indiana, the US. For a complete picture of LY-4101174’s drug-specific PTSR and LoA scores, buy the report here. Blending expert knowledge with cutting-edge ...